# This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

> **NCT05438810** · PHASE3 · UNKNOWN · sponsor: **Ahon Pharmaceutical Co., Ltd.** · enrollment: 312 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Female Breast Cancer

## Interventions

- **DRUG:** FCN-437c,Fulvestrant,Goserelin acetate
- **DRUG:** Placebo,Fulvestrant,Goserelin acetate

## Key facts

- **NCT ID:** NCT05438810
- **Lead sponsor:** Ahon Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-18
- **Primary completion:** 2024-02-18
- **Final completion:** 2024-05-18
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2022-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438810, "This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05438810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*